Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 3;10(9):1682.
doi: 10.3390/healthcare10091682.

Tackling Mantle Cell Lymphoma in Europe

Denis Horgan  1 , Jan Walewski  2 , Igor Aurer  3 , Carlo Visco  4 , Eva Giné  5 , Bogdan Fetica  6 , Mats Jerkeman  7 , Marta Kozaric  1 , Maria Gomes da Silva  8 , Martin Dreyling  9
Affiliations

Tackling Mantle Cell Lymphoma in Europe

Denis Horgan et al. Healthcare (Basel). .

Abstract

An expert panel convened by the European Alliance for Personalized Medicine (EAPM) reflected on achievements and outstanding challenges in Europe in mantle cell lymphoma (MCL). Through the prism of member state experience, the panel noted advances in outcomes over the last decade, but highlighted issues constituting barriers to better care. The list notably included availability of newer treatments, infrastructure and funding for related testing, and shortages of relevant skills and of research support. The prospect of improvements was held to reside in closer coordination and cooperation within and between individual countries, and in changes in policy and scale of investment at both national and EU levels.

Keywords: EU level; MCL; barriers; care; healthcare; infrastructure; mantle cell lymphoma; personalized medicine; policy framework; treatment.

PubMed Disclaimer

Conflict of interest statement

Maria Gomes da Silva is a recipient of research grants: AstraZeneca and Gilead Sciences; Advisory Boards: Janssen, Gilead Sciences, MSD, Celgene, ADC Therapeutics, Roche, Takeda, Novartis; Institutional payments: Roche, Abbvie; Travel support: Roche, Abbvie, Takeda, Janssen, Gilead Sciences; Jan Walewski received consulting fees from Roche, Takeda, Abbvie, Novartis and Gilead, research funding from Roche and GSK/Novartis and lecture honoraria from Roche, Abbvie, Amgen, Novartis and Gilead. Igor Aurer declared financial interest from Roche, Janssen, Astra Zeneca, Sandoz, Pfizer. Eva Gine received honoraria for speaking at symposia, research grant from Isci III, research grant from pharma company (Janssen), advisory board (Gilead/Kite). Martin Dreyling declared research support (institutional) from: Abbvie, Bayer, BMS/Celgene, Gilead/Kite, Janssen, Roche; speaker’s honoraria from: Amgen, Astra Zeneca, Gilead/Kite, Janssen, Eli Lilly and Company, Novartis, Roche; scientific advisory board: Astra Zeneca, Beigene, BMS/Celgene, Gilead/Kite, Janssen, Eli Lilly and Company/Loxo, Novartis, Roche. D.H. and M.K. are employees of the European Alliance for Personalised Medicine, which receives funding from both the public and private sectors. Ivana Cattaneo is an employee of Novartis, receiving compensation (salary, stock options).

References

    1. Aukema S.M., Hoster E., Rosenwald A., Canoni D., Delfau-Larue M.-H., Rymkiewicz G., Thorns C., Hartmann S., Kluin-Nelemans J.C., Hermine O., et al. Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network. Blood. 2018;131:417–420. doi: 10.1182/blood-2017-07-797019. - DOI - PubMed
    1. Bond D., Martin P., Maddocks K. Relapsed Mantle Cell Lymphoma: Current Management, Recent Progress, and Future Directions. J. Clin. Med. 2021;10:1207. doi: 10.3390/jcm10061207. - DOI - PMC - PubMed
    1. Pu J.J., Savani M., Huang N., Epner E.M. Mantle cell lymphoma management trends and novel agents: Where are we going? Ther. Adv. Hematol. 2022;13 doi: 10.1177/20406207221080743. - DOI - PMC - PubMed
    1. Balaji S., Ahmed M., Lorence E., Yan F., Nomie K., Wang M. NF-κB signaling and its relevance to the treatment of mantle cell lymphoma. J. Hematol. Oncol. 2018;11:1–11. doi: 10.1186/s13045-018-0621-5. - DOI - PMC - PubMed
    1. Navarro A., Beà S., Jares P., Campo E. Molecular Pathogenesis of Mantle Cell Lymphoma. Hematol. Clin. North Am. 2020;34:795–807. doi: 10.1016/j.hoc.2020.05.002. - DOI - PMC - PubMed

LinkOut - more resources